Navigation Links
Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
Date:12/20/2013

IRVINE, CA (PRWEB) December 20, 2013

Proove Biosciences, the leader in providing personalized genetic pain medicine services, participated and presented clinical data and research at the Eastern Pain Association’s Annual Meeting on December 7, 2013. The meeting covered current topics in pain medicine and opioid treatment, and took place at the New York Marriott Downtown, in Manhattan.

The EPA offers local and regional scientific meetings to foster an exchange of clinical and scientific information among multidisciplinary health professionals and researchers interested in the field of pain. The Annual EPA Scientific Meeting offered symposia and lectures given by nationally recognized speakers, posters and exhibits designed to appeal to a wide spectrum of specialists and interests.

The EPA’s Annual Meeting concluded a successful and busy year for Proove presenting research throughout the country. Most recently, Proove presented data and findings at the ASRA’s Pain Medicine Meeting, The National Workers Compensation Conference and Expo, and the Common Sense Pain Management Conference.

“Our research and clinical team, along with our aggressive business development efforts have allowed Proove to experience outstanding growth throughout the year,” stated Proove Biosciences President and Founder,Brian Meshkin. “We are the only company providing proprietary testing services in personalized pain medicine. We are happy to have been a part of the EPA’s regional meeting, and exhibiting our work with physicians, psychologists, nurses, and scientists dedicated to pain research.”

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at http://www.prweb.com/releases/2013/12/prweb11440349.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Proove Biosciences CEO Brian Meshkin Wins 2013 Bridging the Gap Award by the Greater Baltimore Committee
2. Proove Biosciences Will Be Exhibiting at the National Workers Compensation Conference and Expo on November 20-22
3. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
4. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
5. Proove Biosciences Announces Sponsorship of National Drug Take Back Day and HC DrugFree
6. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
7. Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
8. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
9. Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
10. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
11. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Geneva, Switerland (PRWEB) , ... January 24, 2017 ... ... the first commercially available malaria Plasmodium falciparum culture panels with standard concentrations of ... panels, which are available in a range of concentrations from six different malaria ...
(Date:1/24/2017)... ... January 23, 2017 , ... Edward ... first-ever recipient of the National Academy of Sciences Prize in Food and Agriculture ... nutrition. , The annual National Academy of Sciences (NAS) Prize in Food and ...
(Date:1/24/2017)... 2017   Instrument Business Outlook ( ... MN ) the 2016 Company of the ... newsletter tracking developments in the analytical and life ... consistently achieved outstanding technical, operational and financial results ... of IBO. "In 2016, Bio-Techne capitalized on opportunities ...
(Date:1/23/2017)... -- Spherix Incorporated (Nasdaq: SPEX ) an intellectual ... and monetization of intellectual property, today provided an update ... Anthony Hayes , Chief Executive Officer of Spherix, stated, ... with shareholders about the status of existing monetization efforts ... patent assets that fit with our current holdings.  We ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical ... 12.14 billion by 2021 from USD 5.31 billion in 2016, at ... ... mainly driven by technological advancements in medical devices, launch of a ... preference for wireless connectivity among healthcare providers, and increasing focus on ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/15/2016)... Advancements in biometrics will radically ... wellbeing (HWW), and security of vehicles by ... vehicles begin to feature fingerprint recognition, iris ... monitoring, brain wave monitoring, stress detection, fatigue ... detection. These will be driven by built-in, ...
Breaking Biology News(10 mins):